Glenmark Pharmaceuticals Inc, USA, has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial for the U.S. market. The product is bioequivalent and therapeutically equivalent to the reference listed drug manufactured by BPI Labs, LLC.
According to IQVIA sales data for the 12 months ending October 2025, the Epinephrine Injection market recorded annual sales of approximately USD 67.6 million. The launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Marc Kikuchi, President and Business Head for North America at Glenmark, said the launch supports the company’s strategy of strengthening its institutional channel presence while improving access to essential medicines.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, established in 1977 by Gracias Saldanha. Originally focused on generic medicines and active pharmaceutical ingredients (APIs), Glenmark has grown into a research-led global healthcare organisation with a presence across branded formulations, generics, and over-the-counter (OTC) segments in more than 80 countries.
The company’s core therapeutic expertise spans respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, supported by multiple R&D centres and manufacturing facilities across India and internationally. Over the years, Glenmark has diversified into innovative drug development and biosimilars while maintaining a strong portfolio of branded generics in high-growth markets.
Its strategy includes discovery of new chemical and biological entities alongside scaling its specialty product offerings. Glenmark has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology, reflecting its evolution beyond traditional generics.
Financially, the company has reported robust revenue growth and expanding demand in key markets such as North America and Europe. Despite quality control challenges in some manufacturing facilities highlighted by regulatory scrutiny, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
